The research for this new drug started in 2000 and it is currently undergoing Phase I clinical trials in conjunction with the Chinese government’s State Food and Drug Administration (SFDA). The company believes that Phase II testing will commence some time in 2008. The company will have the right of first refusal of the manufacturing and marketing of the drug once it is approved by the SFDA as a Category A innovative new drug.
Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations, etc. Jiangsu Institute of Microbiology scientists believe that it might be safer and more reliable for children and elderly patients than current drug offerings in the marketplace.